Reuters logo
4 months ago
BRIEF-Repatha demonstrates reduced need for apheresis in patients with high LDL cholesterol
March 13, 2017 / 1:38 PM / 4 months ago

BRIEF-Repatha demonstrates reduced need for apheresis in patients with high LDL cholesterol

1 Min Read

March 13 (Reuters) - Amgen Inc

* Repatha (evolocumab) demonstrates reduced need for apheresis in patients with high LDL cholesterol in phase 3 study

* Amgen Inc - no new safety concerns were identified in this study

* Amgen - positive top-line results from a phase 3 study evaluating Repatha in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below